UK Markets closed

Medtronic plc (MDT)

NYSE - Nasdaq Real-time price. Currency in USD
Add to watchlist
124.91+0.76 (+0.61%)
As of 1:31PM EDT. Market open.
Sign in to post a message.
  • b
    They had some interesting insights about MDT on ( Definitely made me think twice about the company.
  • J
    $SENS conversation
    $SENS New data released, strong accuracy for 180 day CGM sensor!

  • J
    Joe Smoe
    $SENS conversation
    $SENS will gain market share from $DXCM, $MDT, $PODD, just a matter of time, go $SENS
  • D
    Good interview of MDT'S CEO on CNBC. Future for MDT and its shareholders is looking great.
  • J
    Safest long term investment
  • J
    JL Prestige
    Great results! Lots of cash on hand and #MDT milestone 3 of 4 expected completion this month.... GLTA longs
  • B
    Bill mddb
    The revenue outlook for 9% growth FY 2022 ending 4/30/22 is good news. There is no doubt some catch-up of deferred spending, but still impressive. That's what you see from Stryker, a much smaller base to grow. There should be some LT accumulation coming to keep a bid in for MDT.
  • J
    JL Prestige
    $TMDI conversation
    TMDI up 586% YOY at current SP.... Market has gotten smoked which has caused a pullback in this over the past 3 months, but nothing has changed as #TMDI is in the best position since its inception... Licensing and development $40M deal with the LARGEST med device company in the world in #MDT... Flooded with cash... 160+ patents... Single port robot that fits perfectly as organic growth opportunity for MDT Pelvic division... 2 out of 4 milestones completed with 3rd in the imminent future hopefully this month... New site visit education center in research triangle Chapel Hill, NC... MDT corporate sitting on our board... Mazor was purchased after same development agreement was done with MDT.... Next leg up will be biggest breakout yet, and once we get to the $4 threshold, big money will come in... I am extremely bullish on TMDI in 2021... GLTA fellow longs!
  • T
    MDT beats on top/bottom lines, increases dividend!
  • B
    Bill mddb
    Looks like the outgoing momentum traders are being replaced. Yesterday no doubt saw traders taking profits, but the MDT provided 9% revenue growth this year is very impressive. There should be some accumulation from income & value funds to drive the share price. MDT is a Buffett stock, a dividend aristocrat with some growth. Even if FY 2023, starting 5/1/22 is 5% revenue growth it will be a blockbuster year. They have become good at managing expectations -- the current $5.75 est. for FY 22 should come in over $6. I'm sure they would like to raise the outlook as the year progresses -- just like they were doing before the plague hit.
  • R
    This stock is not worth the price. MDT should be SHORTED. Food for thought Total Expenses 24.3mil
    Total income 3.1mil. Come on.
  • R
    Cover shorty
  • s
    Maintains Oppenheimer Holdings Outperform USD 134 » USD 147
    Maintains Raymond James Financial Outperform USD 128 » USD 135
    Reiterated by Citigroup Buy USD 133 » USD 143
    Maintains SVB Leerink Market Perform USD 129 » USD 138
    Maintains Deutsche Bank Buy USD 134 » USD 149
  • S
    It's like the market doesn't even care at least 14 people have died using Medtronic's HVAD Implantable Heart Pump...
  • I
    NMRD also has a glucose monitoring product for type 2 diabetes that works as well or better then MDTs products. Any comments or anyone here own both stocks ?
  • P
    This is a fantastic re-opening stock. Much of the goods and services provided by MDT have been on the shelf collecting dust. This company is burning rubber out of the gate and is going to leap higher. I can't view it any other way.
  • R
    MDT beats on top/bottom lines, increases dividend and down we go. Insane Trading
  • I
    MDT dibeaties glucose monitoring product is not as good as NMRD products. Anybody here own both MDT & NMRD stock ? ..
  • R
    short MDT. Earning will be bad tomorrow!!
  • B
    Bill mddb
    Love to see the market strength for MDT and medical devices in general - Stryker is also at all time highs. Q4 ending this month shows an analyst est of $1.42 up from $.58 last year as C-19 dropped revenue 26% - it was down 13% the next Q -- Q1 of this year. The composite analyst estimate for FY 2022 is $5.72 -- and FY 22 starts in 10 days -- so at $129 that's a p/e of 22.6 on this years earnings -- doesn't look like an over extended valuation since there is a good chance MDT will beat the Q4 estimates and FY 22 as well.